- |||||||||| Taksta (fusidic acid) / Aceragen
pH-Dependent Spectrum Expansion of Sodium Fusidate Against Bacterial Biothreats (Exhibit and Poster Hall) - May 21, 2022 - Abstract #ASMMicrobe2022ASM_Microbe_1584; To these ends, ACG-701 is a proprietary oral formulation of SF developed by Aceragen for cystic fibrosis and melioidosis...The enhancement of activity at lower pH is of particular interest for combating biothreat agents as the environment of the pulmonary tract (as the primary site of infection during inhalation) and the intracellular lifecycle of some agents necessitates the pathogen may reside in more acidic environments. These results support further development of SF as a useful agent in the biodefense space.
|